75 related articles for article (PubMed ID: 2143888)
1. [The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer].
Imamura Y; Yasutake K; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1501-7. PubMed ID: 2143888
[TBL] [Abstract][Full Text] [Related]
2. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
Caponetti R; Caponetti T; Vici P
Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
4. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
6. [The value of carcinoembryonic antigens in patients with advanced lung cancer: in relation to chemotherapy].
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Takahashi K; Sasaki Y; Ohkura H
Gan To Kagaku Ryoho; 1984 May; 11(5):1056-63. PubMed ID: 6202246
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
9. [Experience with CDDP therapy in advanced and recurrent gastric cancer cases].
Tanemura H; Saji S; Takao H; Kida H; Kunieda K; Miya K; Azuma S; Furuta T; Sakata K; Shimokawa K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2951-5. PubMed ID: 3116948
[TBL] [Abstract][Full Text] [Related]
10. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
11. [Study on endoscopic features in responders to systemic chemotherapy in advanced gastric cancer].
Yasutake K; Tokisue M; Masuda T; Ono S; Yoshimura Y; Yasutake K; Imamura Y; Oya M; Matsushita K
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2519-25. PubMed ID: 2148178
[TBL] [Abstract][Full Text] [Related]
12. Different role of liver dysfunction and damage in increasing serum CA 19-9, TPA, and CEA in patients with pancreatic cancer.
Fabris C; Basso D; Meggiato T; Del Favero G; Piccoli A; Fogar P; Panozzo MP; Faggian D; Naccarato R
Int J Pancreatol; 1990 Jan; 6(1):i-ii. PubMed ID: 2230355
[No Abstract] [Full Text] [Related]
13. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
14. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma.
Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Casaldi V; Cavaliere F; Carlini M; Garofalo A; Rinaldi G
Anticancer Res; 1993; 13(6B):2409-13. PubMed ID: 8135475
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
16. Changes in tumor marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma.
Nakata B; Chung KH; Muguruma K; Yamashita Y; Inoue T; Matsuoka T; Onoda N; Kato Y; Sakurai M; Sowa M
Cancer; 1998 Jul; 83(1):19-24. PubMed ID: 9655288
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between anti-tumor effects and serum hepatocyte growth factor level in patients with liver metastases from gastric cancer treated by induced hypertensive chemotherapy with angiotensin II].
Iwasaki Y; Kitamura M; Arai K
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1874-7. PubMed ID: 9382555
[TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
